Locations:
Search IconSearch
July 2, 2018/Opinion

Pharmacy Benefit Managers Costing Consumers Millions of Dollars

Media Contact

Cleveland Clinic News Service | 216.444.0141

We’re available to shoot custom interviews & b-roll for media outlets upon request.

Media Downloads

CCNS health and medical content is consumer-friendly, professional broadcast quality (available in HD), and available to media outlets each day.

The Featured Image for the post

Cleveland Clinic Chief Pharmacy Officer Scott Knoer writes in STAT News:

Scott Knoer, M.S., Pharm.D., Chief Pharmacy Officer

“Pharmacy benefit managers market themselves as keen negotiators able to squeeze pharmaceutical manufacturers for better deals that save money for insurers, patients, and society. Yet they are turning out to be little more than middlemen, adding scant value but significantly increasing costs. They have no fiduciary responsibility to their customers.”

Read the complete op-ed at: What does PBM stand for? In Ohio (and elsewhere), it’s programs bilking millions

Latest from the Newsroom

Beri Ridgeway, M.D.

Cleveland Clinic Appoints Beri Ridgeway, M.D., as President of Cleveland Clinic London

Genediting Therapy Shows Success Against Severe Sickle Cell Disease

Gene Editing Therapy Shows Success Against Severe Sickle Cell Disease

Cleveland Clinic's Main Campus lobby

Mandel Foundation Donates $50 Million to Improve Access to Care at Cleveland Clinic

Blood pressure cuff

Experimental Monthly Injectable Reduces a Key Regulator of Blood Pressure

GLP-1 injection pen with a stethoscope

Tirzepatide Associated with Lower Risk of Heart and Kidney Damage Compared to Dulaglutide in Patients with Type 2 Diabetes and Cardiovascular Disease

Hospital Care At Home

Cleveland Clinic Introduces Hospital Care At Home in Ohio

Image of a scaled and tape measure

What Happens When Patients Stop Taking GLP-1 Drugs? New Cleveland Clinic Study Reveals Real World Insights

Illustration of digital medical records

AI-Driven Chart Review Accurately Identifies Potential Rare Disease Trial Participants in New Study